Navigation Links
Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
Date:11/6/2008

SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced top-line results from its Phase 1 clinical trial of an oral formulation of picoplatin in patients with solid tumors showing that picoplatin achieves linear and dose-dependent plasma exposure when given by the oral route. The results demonstrated that exposure to orally administered picoplatin was linear at doses below 200 mg, and that maximum exposure to orally administered picoplatin was achieved at doses of 200 mg or greater indicating sufficient bioavailability to support further clinical studies.

"Achieving sufficient bioavailability with oral picoplatin is extremely encouraging and supports further clinical development of an oral formulation of the drug, as it may provide a more convenient, flexible dosing routine for patients who would benefit from picoplatin," said Robert De Jager, M.D., chief medical officer of Poniard. "Orally administered picoplatin may be desirable for cancer patients receiving radiation therapy and in combination with other oral therapies."

Phase 1 Study Design and Results

Poniard's randomized, open-label, dose-ranging Phase 1 study was conducted at clinical sites in the United States. The trial compared the bioavailability, pharmacokinetics, pharmacodynamics and safety of picoplatin administered orally with picoplatin administered intravenously in patients with advanced solid tumor malignancies. Bioavailability refers to the fraction of an administered dose of an unchanged drug that reaches systemic circulation. In the first part of this two-part trial, patients with advanced solid tumor malignancies were randomized to
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... NEW YORK, Aug 20, 2014 Reportlinker.com ... available in its catalogue: Global Patient ... This report analyzes the worldwide markets ... following Product Segments: Floor Scales, Infant & Baby ... report provides separate comprehensive analytics for the US, ...
(Date:8/20/2014)... SAN MARCOS, Texas , Aug. 20, 2014 ... purchase of five diverse sets of patent families ... and major innovation driver for Bayer AG of ... The patents acquired provide broad intellectual property ... achieved in economical high-volume quantum dot (QD) manufacturing. ...
(Date:8/20/2014)... 20, 2014 Phase I Trial ... US  KalVista Pharmaceuticals ("KalVista"), an ophthalmology company ... announces that it has begun a Phase I, First ... KVD001, for the treatment of DME. The study,s Principal ... Eye Institute, Joslin Diabetes Center; Harvard Medical School Department ...
Breaking Medicine Technology:Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... Therapeutics,(Amex: CXM ) and its operating ... from a preclinical study, demonstrating a new ... for the potential,treatment of acute myocardial infarction ... Central (BMC) Cardiovascular Disorders (2008, 8:7, April,10, ...
... Regimen Designed to Avoid Risk of Toxicity ... Associated with Nucleoside Class of HIV Drugs, ... ) today announced that it has initiated a Phase ... in first-line therapy of adult treatment-naive HIV-infected patients,with R5-type ...
Cached Medicine Technology:Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 2Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 3Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 4Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 5Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 6Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 7Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 8Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 9Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 10Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 11Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 12Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 2Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 3Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 4Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 5Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 6
(Date:8/20/2014)... 42 percent of women underwent breast reconstruction following ... with foregoing reconstruction included being black, having a ... Monica Morrow, M.D., of the Memorial Sloan Kettering ... The Women,s Health and Cancer Rights Act in ... a mastectomy. Still, most women who undergo a ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Hundreds of ... behalf of women who were allegedly injured due to ... in New Jersey’s Bergen County Superior Court, Bernstein Liebhard ... on August 15, 2014, the Court has established procedures ... Mirena lawsuits that are part of the proceeding’s initial ...
(Date:8/20/2014)... Dennis Thompson HealthDay Reporter ... may help older women avoid a condition that causes a ... postmenopausal women had a 10 percent lower risk of developing ... report in the Aug. 20 issue of the Journal ... this protection against the heart rhythm disorder even if they ...
(Date:8/20/2014)... August 20, 2014 Park Cities Pet ... NAPPS Presents 4 Pets supply donation drive that benefits the ... a national campaign that coincides with the Humane Society of ... November 2nd through 8th, 2014. , As part of their ... supply and monetary donations for the Presents 4 Pets drive ...
(Date:8/20/2014)... Salt Lake City, Utah (PRWEB) August 20, 2014 ... the Inc. 500’s 2014 list of the nation’s fastest growing ... overall growth in the health care sector. Connexion Point is ... specializes in contact centers in Medicare and Medicaid, and its ... in the nation. Connexion Point employs 1,000 people and has ...
Breaking Medicine News(10 mins):Health News:Patient perspectives on breast reconstruction following mastectomy 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 3Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 4Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 3Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 2Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 3Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 4Health News:With 3943.8% Growth, Connexion Point, a Leader in Contact Centers for Health Care, Ranks 86th on the Inc. 500 List as One of the Nation’s Fastest Growing Companies 2
... vaccination and a lack of time as main reasons adults avoid ... ... December 10, 2008 -- A new survey of approximately 4,000 American ... against the flu this season. The survey is the first of ...
... Dec. 10 Markel Corporation is,pleased to announce the ... insurance product. DataBreach(SM) helps businesses manage,risk associated with their ... information in their custody or care. , ... to the increase in identity theft,that has been plaguing ...
... might yield new insights into eating disorders, experts say ... verifying what many overeaters have suspected for a long ... sweetener seems to prompt the same chemical changes in ... as cocaine and heroin. , The findings were to ...
... Healthcare Management Systems,Inc.(R) (HMS) hospital customers completed three paintings ... were entered into a drawing,to receive the paintings to ... Recipients of the 4-foot by 6-foot, multiple-canvas paintings were,announced ... HMS, annual,conference. , , ...
... to Attempt to Prevent Complete Vision Loss in Patient ... Dec. 10 NeoVista, Inc., announced today that ... the company,s "compassionate case" waiver to utilize its novel ... with an advanced form of the disease who did ...
... children, new government survey says , , WEDNESDAY, Dec. ... U.S. adults and 12 percent of children use some ... government survey finds. , Complementary and alternative medicine -- ... a collection of wide-ranging medical and health care systems, ...
Cached Medicine News:Health News:Mid-Season Flu Immunization Rates are Too Low 2Health News:Mid-Season Flu Immunization Rates are Too Low 3Health News:Mid-Season Flu Immunization Rates are Too Low 4Health News:Mid-Season Flu Immunization Rates are Too Low 5Health News:Markel Corporation Announces New DataBreach(SM) Privacy Liability Coverage 2Health News:Study Suggests Sugar May Be Addictive 2Health News:Study Suggests Sugar May Be Addictive 3Health News:HMS Donates Hospital Art 2Health News:FDA Grants NeoVista's Request to Utilize Novel Wet AMD Treatment in Compassionate Case 2Health News:FDA Grants NeoVista's Request to Utilize Novel Wet AMD Treatment in Compassionate Case 3Health News:38% of U.S. Adults Use Alternative Treatments 2Health News:38% of U.S. Adults Use Alternative Treatments 3
Black elastomer. Smooth finish. Non-Sterile....
All oral and nasal airways are manufactured with smooth, rounded edges for increased patient comfort and safety., ,Portex® offers a broad selection of airways for a variety of clinical applicati...
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
Medicine Products: